A Landscape of Pharmacogenomic Interactions in Cancer. Cell 166: 2016 740-754 |
912 |
Assessment of pharmacogenomic agreement. F1000Res 5: 2016 825 |
18 |
Revisiting inconsistency in large pharmacogenomic studies. F1000Res 5: 2016 2333 |
44 |
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun 9: 2018 2024 |
47 |
Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560: 2018 325-330 |
401 |
Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting. BMC Genomics 19: 2018 604 |
38 |
The germline genetic component of drug sensitivity in cancer cell lines. Nat Commun 9: 2018 3385 |
23 |
An RNAi screen in human cell lines reveals conserved DNA damage repair pathways that mitigate formaldehyde sensitivity. DNA Repair (Amst) 72: 2018 1-9 |
8 |
Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects. Genome Biol 20: 2019 27 |
20 |
Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569: 2019 503-508 |
1381 |
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nat Commun 10: 2019 2198 |
59 |
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nat Commun 10: 2019 2674 |
126 |
Copy number variation is highly correlated with differential gene expression: a pan-cancer study. BMC Med Genet 20: 2019 175 |
107 |
Chromosome arm aneuploidies shape tumour evolution and drug response. Nat Commun 11: 2020 449 |
41 |
Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns. Sci Adv 6: 2020 eaba1862 |
32 |
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens. Patterns (N Y) 1: 2020 100065 |
5 |
A first-generation pediatric cancer dependency map. Nat Genet 53: 2021 529-538 |
50 |
Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines. Elife 10: 2021 e66198 |
5 |
Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response. Int J Mol Sci 22: 2021 10135 |
1 |
Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma. BMC Med 20: 2022 175 |
3 |
Mutational signatures are markers of drug sensitivity of cancer cells. Nat Commun 13: 2022 2926 |
24 |
CNpare: matching DNA copy number profiles. Bioinformatics 38: 2022 3638-3641 |
2 |